Trial Profile
A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-Acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Risperidone (Primary) ; Olanzapine
- Indications Bipolar I disorders
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 16 Feb 2010 Actual patient number changd from 585 to 586 added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual patient number changd from 585 to 586 added as reported by ClinicalTrials.gov.
- 30 Jun 2009 Actual patient number (585) added as reported by ClinicalTrials.gov.